scholarly journals Impact of IDDM2 on disease pathogenesis and progression in children with newly diagnosed type 1 diabetes: reduced insulin antibody titres and preserved beta cell function

Diabetologia ◽  
2005 ◽  
Vol 49 (1) ◽  
pp. 71-74 ◽  
Author(s):  
L. B. Nielsen ◽  
◽  
H. B. Mortensen ◽  
F. Chiarelli ◽  
R. Holl ◽  
...  
1990 ◽  
Vol 3 (1) ◽  
pp. 56
Author(s):  
J.J. Cook ◽  
I.L. Hudson ◽  
G.A. Werther ◽  
G.L. Warne ◽  
J.M. Court ◽  
...  

2012 ◽  
Vol 13 (7) ◽  
pp. 564-571 ◽  
Author(s):  
Maria J. Redondo ◽  
Luisa M. Rodriguez ◽  
Mirna Escalante ◽  
E. O'Brian Smith ◽  
Ashok Balasubramanyam ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Lotte B. Nielsen ◽  
Cheng Wang ◽  
Kaspar Sørensen ◽  
Claus H. Bang-Berthelsen ◽  
Lars Hansen ◽  
...  

This study aims to identify key miRNAs in circulation, which predict ongoing beta-cell destruction and regeneration in children with newly diagnosed Type 1 Diabetes (T1D). We compared expression level of sera miRNAs from new onset T1D children and age-matched healthy controls and related the miRNAs expression levels to beta-cell function and glycaemic control. Global miRNA sequencing analyses were performed on sera pools from two T1D cohorts (n= 275 and 129, resp.) and one control group (n= 151). We identified twelve upregulated human miRNAs in T1D patients (miR-152, miR-30a-5p, miR-181a, miR-24, miR-148a, miR-210, miR-27a, miR-29a, miR-26a, miR-27b, miR-25, miR-200a); several of these miRNAs were linked to apoptosis and beta-cell networks. Furthermore, we identified miR-25 as negatively associated with residual beta-cell function (est.: −0.12,P= 0.0037), and positively associated with glycaemic control (HbA1c) (est.: 0.11,P= 0.0035) 3 months after onset. In conclusion this study demonstrates that miR-25 might be a “tissue-specific” miRNA for glycaemic control 3 months after diagnosis in new onset T1D children and therefore supports the role of circulating miRNAs as predictive biomarkers for tissue physiopathology and potential intervention targets.


PLoS ONE ◽  
2011 ◽  
Vol 6 (3) ◽  
pp. e17554 ◽  
Author(s):  
Stephan Martin ◽  
Christian Herder ◽  
Nanette C. Schloot ◽  
Wolfgang Koenig ◽  
Tim Heise ◽  
...  

PLoS ONE ◽  
2011 ◽  
Vol 6 (11) ◽  
pp. e26471 ◽  
Author(s):  
John M. Lachin ◽  
Paula L. McGee ◽  
Carla J. Greenbaum ◽  
Jerry Palmer ◽  
Mark D. Pescovitz ◽  
...  

BMJ Open ◽  
2017 ◽  
Vol 7 (10) ◽  
pp. e017178 ◽  
Author(s):  
Lidia Groele ◽  
Hania Szajewska ◽  
Agnieszka Szypowska

IntroductionRecent evidence has demonstrated that, among other factors, dysbiosis (imbalances in the composition and function of the gut microbiota) may be relevant in the development of type 1 diabetes (T1D). Thus, gut microbiota may be a target for improving outcomes in subjects with T1D. The aim of the study is to examine the effects ofLactobacillus rhamnosusGG andBifidobacterium lactisBb12 on beta-cell function in children with newly diagnosed T1D.Methods and analysisA total of 96 children aged 8 to 17 years with newly diagnosed T1D, confirmed by clinical history and the presence of at least one positive autoantibody, will be enrolled in a double-blind, randomised, placebo-controlled trial in which they will receiveL. rhamnosusGG andB. lactisBb12 at a dose of 109colony-forming units or an identically appearing placebo, orally, once daily, for 6 months. The follow-up will be for 12 months. The primary outcome measures will be the area under the curve of the C-peptide level during 2-hour responses to a mixed meal.Ethics and disseminationThe Bioethics Committee approved the study protocol. The findings of this trial will be submitted to a peer-reviewed paediatric journal. Abstracts will be submitted to relevant national and international conferences.Trial registration numberNCT03032354; Pre-results.


Sign in / Sign up

Export Citation Format

Share Document